Pfizer Ventures, billed as an existing investor, contributed to the $72.5m close of the antibody-drug conjugate developer's latest round.
US-based antibody therapeutics developer BioAtla completed a $72.5m series D round yesterday backed by pharmaceutical firm Pfizer’s corporate venture capital unit, Pfizer Ventures.
Healthcare investment firms Soleus Capital and HBM Healthcare Investments co-led the round, which included Cormorant Asset Management, Farallon Capital, Pappas Capital, Boxer Capital, funds managed by Janus Henderson and an unnamed institutional investor.
BioAtla has built a technology platform to develop conditionally active biologics (CABs) – proteins which are activated or deactivated with changes to surrounding physiology,…
